• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.

作者信息

Ma Jiexian, Sun Shunrong, Hu Yingwei, Wu Min, Shen Lin, Fulati Wulipan, Huang Zilan, Qian Wensi, Chen Pingping, Chen Mingyue, Xie Yanhui

机构信息

Department of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.

出版信息

Bone Marrow Transplant. 2022 Oct;57(10):1612-1614. doi: 10.1038/s41409-022-01766-8. Epub 2022 Jul 25.

DOI:10.1038/s41409-022-01766-8
PMID:35879604
Abstract
摘要

相似文献

1
Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.高危弥漫性大B细胞淋巴瘤一线自体干细胞移植中的新型预处理方案
Bone Marrow Transplant. 2022 Oct;57(10):1612-1614. doi: 10.1038/s41409-022-01766-8. Epub 2022 Jul 25.
2
[Progress of Auto-HSCT for Treatment of DLBCL--Review].[自体造血干细胞移植治疗弥漫大B细胞淋巴瘤的研究进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Dec;26(6):1841-1846. doi: 10.7534/j.issn.1009-2137.2018.06.044.
3
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.利妥昔单抗-BEAM 方案与 BEAM 预处理方案在接受自体移植的弥漫性大 B 细胞淋巴瘤患者中的疗效比较。
Cancer. 2020 May 15;126(10):2279-2287. doi: 10.1002/cncr.32752. Epub 2020 Feb 12.
4
The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase.血清乳酸脱氢酶升高的晚期弥漫性大B细胞淋巴瘤患者中，根据前期自体干细胞移植进行分子分类的不同作用
Ann Hematol. 2016 Sep;95(9):1491-501. doi: 10.1007/s00277-016-2729-4. Epub 2016 Jun 21.
5
Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.高危双表达弥漫性大 B 细胞淋巴瘤患者的 upfront 自体造血干细胞移植。
Ann Hematol. 2020 Sep;99(9):2149-2157. doi: 10.1007/s00277-020-04043-0. Epub 2020 May 10.
6
Safety and efficacy of high-dose cyclophosphamide, etoposide and ranimustine regimen followed by autologous peripheral blood stem cell transplant for patients with diffuse large B-cell lymphoma.大剂量环磷酰胺、依托泊苷和雷莫司汀方案序贯自体外周血干细胞移植治疗弥漫性大B细胞淋巴瘤患者的安全性和疗效
Leuk Lymphoma. 2014 Nov;55(11):2514-9. doi: 10.3109/10428194.2014.889827. Epub 2014 Mar 17.
7
R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study.R-CHOP-14 对比 R-CHOP-14/CHASER 方案用于弥漫性大 B 细胞淋巴瘤患者的一线自体造血干细胞移植：JCOG0908 研究。
Cancer Sci. 2020 Oct;111(10):3770-3779. doi: 10.1111/cas.14604. Epub 2020 Sep 11.
8
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.用钇-90替伊莫单抗联合BEAM方案进行预处理后自体干细胞移植治疗难治性非霍奇金弥漫性大B细胞淋巴瘤：一项前瞻性、多中心、II期临床试验的结果
Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25.
9
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.复发弥漫性大B细胞淋巴瘤自体造血干细胞移植中，预处理化疗的每体重剂量对粘膜炎严重程度及复发风险的影响。
Br J Haematol. 2008 Oct;143(2):268-73. doi: 10.1111/j.1365-2141.2008.07342.x. Epub 2008 Aug 10.
10
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.一项关于奥英妥珠单抗和利妥昔单抗的2期研究，随后对复发/难治性弥漫性大B细胞淋巴瘤患者进行自体干细胞移植。
Leuk Lymphoma. 2015;56(10):2863-9. doi: 10.3109/10428194.2015.1017821. Epub 2015 Mar 29.

引用本文的文献

1
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.与BEAM方案相比，基于米托蒽醌的新型预处理方案可使外周T细胞淋巴瘤患者获得显著的生存获益。
Cancer Med. 2024 Dec;13(23):e70476. doi: 10.1002/cam4.70476.
2
Maintenance regimen of GM-CSF with rituximab and lenalidomide improves survival in high-risk B-cell lymphoma by modulating natural killer cells.GM-CSF 联合利妥昔单抗和来那度胺维持治疗通过调节自然杀伤细胞改善高危 B 细胞淋巴瘤的生存。
Cancer Med. 2023 Jun;12(12):12975-12985. doi: 10.1002/cam4.5969. Epub 2023 Apr 20.

本文引用的文献

1
Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.改良的柔红霉素方案预处理后自体造血干细胞移植治疗侵袭性 B 细胞非霍奇金淋巴瘤患者。
Sci Rep. 2021 Feb 19;11(1):4273. doi: 10.1038/s41598-021-81944-8.
2
Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.改良的脑电活动图作为淋巴瘤患者接受自体造血干细胞移植的预处理方案。
Bone Marrow Transplant. 2018 Jan;53(1):91-93. doi: 10.1038/bmt.2017.206. Epub 2017 Oct 2.
3
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
利妥昔单抗密集化疗联合或不联合大剂量化疗和自体干细胞移植治疗高危弥漫性大 B 细胞淋巴瘤（DLCL04）：一项多中心、开放标签、随机、对照、3 期研究的最终结果。
Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.
4
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.随机对照试验比较 R-CHOP 与高危弥漫大 B 细胞淋巴瘤患者的高剂量序贯化疗。
J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.
5
Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.非霍奇金淋巴瘤中CBV、BEAM和BEAC大剂量化疗后自体造血干细胞移植的比较：疗效与毒性
Asia Pac J Clin Oncol. 2017 Oct;13(5):e423-e429. doi: 10.1111/ajco.12610. Epub 2017 Jan 19.
6
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.自体移植作为侵袭性非霍奇金淋巴瘤的巩固治疗。
N Engl J Med. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077.
7
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.异环磷酰胺、伊达比星和依托泊苷用于复发/难治性霍奇金病或非霍奇金淋巴瘤：一种在自体干细胞移植前具有高缓解率的挽救方案。
Biol Blood Marrow Transplant. 2005 Sep;11(9):688-97. doi: 10.1016/j.bbmt.2005.05.014.
8
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.高剂量疗法对预后不良的侵袭性非霍奇金淋巴瘤的生存获益：前瞻性LNH87-2方案的最终分析——一项成人淋巴瘤研究组的研究
J Clin Oncol. 2000 Aug;18(16):3025-30. doi: 10.1200/JCO.2000.18.16.3025.
9
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.一项针对难治性或复发性侵袭性及高级别非霍奇金淋巴瘤患者的伊达比星、异环磷酰胺和依托泊苷（IIVP - 16）的II期研究。
Leuk Lymphoma. 1997 Feb;24(5-6):513-22. doi: 10.3109/10428199709055588.
10
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.自体骨髓移植与挽救性化疗治疗化疗敏感型非霍奇金淋巴瘤复发的比较。
N Engl J Med. 1995 Dec 7;333(23):1540-5. doi: 10.1056/NEJM199512073332305.